← Back to headlines
Regeneron's Otarmeni Application Accepted for EMA Review
Regeneron (REGN) has announced that the European Medicines Agency (EMA) has accepted its application for Otarmeni for review.
31 May, 08:23 — 31 May, 08:23
Sources
Showing 1 of 1 sources
Related Stories
Fed Chair Warsh Warns of Rate Hikes if U.S. Inflation Persists at Jackson Hole
31m ago
Trump Administration Proposes Plan for Farmers to Process Their Own Meat
35m ago
Rubrik Shares Fall After Disappointing Second-Quarter Earnings and Weak Guidance
41m ago
Marvell Shares Drop Despite Strong Earnings and Data Center Growth Forecast
54m ago